market folly

George Soros' family office Soros Fund Management has filed  13G with the SEC regarding shares of Plasmatech Biopharma (PTBI).  Per the filing, Soros Fund has disclosed a 5.17% ownership stake in the company with over 1.16 million shares.

This marks an increase of 916,677 shares since the end of 2014.  The filing was made due to activity on April 22nd.

Per Google Finance, Plasmatech Biopharma is "formerly Access Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing a range of pharmaceutical products primarily based upon nanopolymer chemistry technologies and other drug delivery technologies. The key products for the Company are MuGard, which manages oral mucositis, CobOral, a preclinical nanopolymer for oral delivery of a number of peptides and therapeutics and Cobacyte, its anti-cancer technology to protect normal tissues."